Filing Details

Accession Number:
0001104659-18-017142
Form Type:
13D Filing
Publication Date:
2018-03-13 17:00:54
Filed By:
Van Herk Investments B.v.
Company:
Ablynx Nv
Filing Date:
2018-03-13
SEC Url:
13D Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Van Herk Investments B.V. S.S. or 4,831,247 0 4,831,247 0 4,831,247 6.4%
Van Herk Private Equity Investments B.V. S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
Stichting Administratiekantoor Penulata S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
Van Herk Management Services B.V. S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V. S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
A. van Herk Holding B.V. S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
Stichting Administratiekantoor Abchrys S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
Adrianus van Herk S.S. or 0 4,831,247 0 4,831,247 4,831,247 6.4%
Filing

 

 

UNITED STATES

 

 

SECURITIES AND EXCHANGE COMMISSION

 

 

Washington, D.C. 20549

 

 

 

 

 

SCHEDULE 13D/A

 

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)

 

Ablynx NV

(Name of Issuer)

 

Ordinary Shares, no par value, and American Depositary Shares, each of which represents one Ordinary Share

(Title of Class of Securities)

 

BE0003877942 (Ordinary Shares)

00372Y105 (American Depositary Shares)

(CUSIP Number)

 

March 9, 2018

(Date of Event Which Requires Filing of this Statement)

Van Herk Investments B.V.

Lichtenauerlaan 30

3062 ME Rotterdam

The Netherlands

Telephone: +31-10-241-1555

Attn: Erik Esveld

 

with a copy to:

 

Baker & McKenzie LLP

452 Fifth Avenue

New York, NY  10018

Telephone:  +1-212-626-4100

Attn:  Jan J.H. Joosten

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box x.

 


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Van Herk Investments B.V.

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
BK AF WC

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
4,831,247

 

8

Shared Voting Power
0

 

9

Sole Dispositive Power
4,831,247

 

10

Shared Dispositive Power
0

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *      o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
CO

 

2


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Van Herk Private Equity Investments B.V.

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
OO

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
CO

 

3


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Stichting Administratiekantoor Penulata

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
OO

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
OO

 

4


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Van Herk Management Services B.V.

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
OO

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
CO

 

5


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V.

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
OO

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
CO

 

6


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
A. van Herk Holding B.V.

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
OO

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
CO

 

7


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Stichting Administratiekantoor Abchrys

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
OO

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
OO

 

8


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

1

Name of Reporting Persons
Adrianus van Herk

S.S. or I.R.S. Identification No. of Above Persons

(Intentionally Omitted)

 

 

2

Check the Appropriate Box if a Member of a Group*

 

 

(a)

 o

 

 

(b)

 o

 

 

3

SEC Use Only

 

 

4

Source of Funds
PF

 

 

5

Check Box if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)     o

 

 

6

Citizenship or Place of Organization
The Netherlands

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7

Sole Voting Power
0

 

8

Shared Voting Power
4,831,247

 

9

Sole Dispositive Power
0

 

10

Shared Dispositive Power
4,831,247

 

 

11

Aggregate Amount Beneficially Owned by Each Reporting Person
4,831,247

 

 

12

Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares *     o

 

 

13

Percent of Class Represented by Amount in Row (11)
6.4%

 

 

14

Type of Reporting Person*
IN

 

9


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

Item 1.                         Security and Issuer

 

(a)                                 Name of Issuer:

 

Ablynx NV, a Belgian corporation (Ablynx)

 

(b)                                 Address of Issuers Principal Executive Offices:

 

Technologiepark 21
9052 Ghent/Zwijnaarde
Belgium

 

(c)                                  Class of Security

 

Ordinary Shares, no par value (Ordinary Shares), and American Depositary Shares (ADSs and, together with the Ordinary Shares, the Common Stock), each of which represents one Ordinary Share.

 

Item 2.                         Identity and Background

 

(a)                                 Name of Person Filing:

 

This statement is being filed by (i) Van Herk Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (VHI), with respect to Common Stock beneficially owned by it, (ii) Van Herk Private Equity Investments B.V., a private company with limited liability incorporated under the laws of the Netherlands (VHPI), with respect to Common Stock beneficially owned by VHI, (iii) Stichting Administratiekantoor Penulata, a foundation organized under the laws of the Netherlands (Penulata), with respect to Common Stock beneficially owned by VHI and VHPI, (iv) Van Herk Management Services B.V., a private company with limited liability incorporated under the laws of the Netherlands (VHMS), with respect to Common Stock beneficially owned by VHI and VHPI, (v) Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V., a private company with limited liability incorporated under the laws of the Netherlands (OGBBA), with respect to Common Stock beneficially owned by VHI, VHPI and VHMS, (vi) A. van Herk Holding B.V., a private company with limited liability incorporated under the laws of the Netherlands (Holdings), with respect to Common Stock beneficially owned by VHI, VHPI, VHMS and OGBBA, (vii) Stichting Administratiekantoor Abchrys, a foundation organized under the laws of the Netherlands (Abchrys), with respect to Common Stock beneficially owned by VHI, VHPI, VHMS, OGBBA and Holdings, and (viii) Adrianus van Herk (Mr. van Herk) with respect to Common Stock beneficially owned by VHI, VHPI, VHMS, OGBBA, Holdings, Penulata and Abchrys.

 

Each of Mr. van Herk, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys disclaims beneficial ownership of the securities covered by this statement.

 

10


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

(b)                                 Address of Principal Business Office or, if none, Residence:

 

The principal business address of each of Mr. van Herk, VHI, VHPI, Penulata, VHMS, OGBBA, Holdings and Abchrys is:

 

Lichtenauerlaan 30

3062 ME Rotterdam

The Netherlands

 

(c)                                  Principal Occupation, Employment or Business:

 

Mr. van Herk is (i) an investor, (ii) the holder of all of the depositary receipts issued by Penulata and Abchrys, (iii) the sole board member of Penulata and Abchrys, and (iii) the sole managing director of VHMS, OGBBA and Holdings.  Penulata holds substantially all of the issued and outstanding shares of VHPI.  VHPI is the sole shareholder of VHI.  VHI is principally engaged in making investments.  Abchrys holds substantially all of the issued and outstanding shares of Holdings.  Holdings is the sole shareholder of OGBBA.  OGBBA is the sole shareholder of VHMS and is principally engaged in making investments.  VHMS is the sole managing director of VHI and VHPI.

 

(d)                                 Convictions or Civil Proceedings:

 

During the past five years, none of the Reporting Persons and, to the knowledge of the Reporting Persons, none of the executive officers or directors of the Reporting Persons, if applicable, has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(e)                                  Citizenship:

 

Each of VHI, VHPI, VHMS, OGBBA and Holdings is a private company with limited liability incorporated under the laws of the Netherlands.  Penulata and Abchrys are Netherlands foundations.  Mr. van Herk is a citizen of the Netherlands.

 

Item 3.                         Source and Amount of Funds or Other Consideration.

 

In August 2016, VHI acquired its initial investment in Ablynx from Mr. van Herk, who had acquired the Common Stock in open market transactions over time.  From time to time since August 2016, (i) VHI has acquired Common Stock in open market transactions for its own account and (ii) Mr. van Herk has acquired Common Stock in open market transactions for the account of VHI pursuant to an agreement between Mr. van Herk and VHI (the Account Agreement).  In addition, VHI purchased Common Stock in the U.S. initial public offering of Ablynx.  From time to time, shares of Common Stock held by Mr. van Herk pursuant to the Account Agreement are transferred to VHI.  The sources of the funding for the purchase of Common Stock were the general working capital of VHI or the personal funds of Mr. van Herk, as applicable.  The working capital of VHI is in part funded by margin loans provided

 

11


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

by various banks.  The shares of Common Stock held by VHI, together with certain other securities, have been pledged as security for such loans.

 

Item 4.                         Purpose of the Transaction

 

The Reporting Persons initially acquired the Common Stock for investment purposes.

 

On January 8, 2018, Novo Nordisk A/S, a Danish corporation (Novo Nordisk), publicly announced that it had made a non-binding conditional proposal on December 22, 2017 to acquire Ablynx for 28.00 per Common Share in cash and one Conditional Value Right with total potential cash payments over time of up to 2.50 per Common Share (the Novo Nordisk Proposed Offer).

 

On January 8, 2018, Ablynx publicly announced that it had rejected the Novo Nordisk Proposed Offer because it was not in the best interest of Ablynx and its shareholders as it fundamentally undervalued caplacizumab, the Ablynx pipeline, platform, technology, people, and know how.

 

The Reporting Persons believe that the price offered per share of Common Stock in the Novo Nordisk Proposed Offer undervalues Ablynx.

 

On January 18, 2018, VHI publicly announced that it agreed with the opinion of the board of directors of Ablynx that the Novo Nordisk Proposed Offer undervalued caplacizumab, the Ablynx pipeline, platform, technology, people, and know how.  VHI stated that it was willing to consider any offer for Ablynx by Novo Nordisk, or any other bidder, that properly reflected the value of the company.  VHI further stated that if a potential offer properly reflected the value of Ablynx (as determined in VHIs sole discretion), VHI intended to encourage the Board of Directors of Ablynx to enter into an open dialogue with the bidder.  A copy of VHIs press release (the Press Release) is attached hereto as Exhibit 1 and is incorporated herein by reference.

 

On January 29, 2018, Ablynx announced that it had entered into a definitive agreement with Sanofi, a French corporation (Sanofi), pursuant to which, subject to the satisfaction of certain conditions, Sanofi will offer to acquire Ablynx for 45 per Common Share in cash (the Sanofi Proposed Offer).

 

No agreement, arrangement or understanding exists between the Reporting Persons, on the other hand, and Ablynx, Novo Nordisk or Sanofi, on the other hand.  The Reporting Persons may seek in the future to communicate, and have previously communicated, with Ablynx, Novo Nordisk and Sanofi.  The Reporting Persons may, from time to time, and at any time, acquire additional Common Stock or write or purchase options on Common Stock in the open market or otherwise and reserve the right to dispose of any or all of the Common Stock in the open market or otherwise, at any time and from time to time, and to engage in any hedging or similar transactions with respect to the Common Stock.  Subject to applicable law, the Reporting Persons may also from time to time undertake such other actions as it considers necessary to seek to enhance shareholder value at Ablynx, including without limitation, actions intended to cause changes to the business, strategy or board composition of Ablynx. The Reporting Persons reserve the right to tender their shares of Common Stock in the Novo Nordisk Proposed Offer, as it may be modified or revised from time to time, the Sanofi Proposed Offer, as it may be modified or revised from time to time, or in any other offer for the Common Stock without notice.

 

Except as described above, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in Item 4 of Schedule 13D of the Securities Exchange Act of 1934, as amended, but the Reporting Persons reserve the right to propose, undertake or participate in any such actions in the future.

 

12


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

Item 5.                         Interest in Securities of the Issuer

 

The percentages used herein are calculated based upon the 75,073,886 shares of Common Stock issued and outstanding as reported by Ablynx in its press release captioned Ablynx Announces Conversion of Bonds dated February 28, 2018 and made available on its website at www.ablynx.com.

 

Prior to January 18, 2018 (the day on which VHI issued the Press Release), the Reporting Persons were passive investors in Ablynx.  After such date, the Reporting Persons may no longer be deemed to be passive investors.  Certain of the Reporting Persons filed a Schedule 13G with the Securities and Exchange Commission on November 30, 2017 with respect to their beneficial ownership of Common Stock.  The Schedule 13D filed on January 23, 2018 (the Original Schedule 13D) superseded such Schedule 13G. The Original Schedule 13D was amended and restated in its entirety by Amendment No. 1 to Schedule 13D filed on February 27, 2018 (the First Amended and Restated Schedule 13D). This Amendment No. 2 to Schedule 13D (this Amendment No. 2) is being filed in connection with the sale by the Reporting Persons of certain shares of Common Stock. This Amendment No. 2 amends and restates the First Amended and Restated Schedule 13D in its entirety.

 

(a)                                 Number of shares of Common Stock beneficially owned by each of the Reporting Persons:  4,831,247

 

Percent of class:  6.4%

 

(b)                                 Number of shares as to which such person has:

 

VHI

 

i.

Sole power to vote or direct the vote:

4,831,247

 

 

 

ii.

Shared power to vote or direct the vote:

0

 

 

 

iii.

Sole power to dispose or direct the disposition of:

4,831,247

 

 

 

iv.

Shared power to dispose or direct the disposition of:

0

 

VHI has the sole power to vote or direct the vote, and to dispose or to direct the disposition of, the Common Stock beneficially owned by it.

 

13


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

VHPI

 

i.

Sole power to vote or direct the vote:

0

 

 

 

ii.

Shared power to vote or direct the vote:

4,831,247

 

 

 

iii.

Sole power to dispose or direct the disposition of:

0

 

 

 

iv.

Shared power to dispose or direct the disposition of:

4,831,247

 

VHPI shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHI.

 

Penulata

 

i.

Sole power to vote or direct the vote:

0

 

 

 

ii.

Shared power to vote or direct the vote:

4,831,247

 

 

 

iii.

Sole power to dispose or direct the disposition of:

0

 

 

 

iv.

Shared power to dispose or direct the disposition of:

4,831,247

 

Penulata shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHPI.

 

VHMS

 

i.

Sole power to vote or direct the vote:

0

 

 

 

ii.

Shared power to vote or direct the vote:

4,831,247

 

 

 

iii.

Sole power to dispose or direct the disposition of:

0

 

 

 

iv.

Shared power to dispose or direct the disposition of:

4,831,247

 

VHMS shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of it being the sole managing director of VHI and VHPI.

 

14


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

OGBBA

 

i.

Sole power to vote or direct the vote:

0

 

 

 

ii.

Shared power to vote or direct the vote:

4,831,247

 

 

 

iii.

Sole power to dispose or direct the disposition of:

0

 

 

 

iv.

Shared power to dispose or direct the disposition of:

4,831,247

 

OGBBA shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in VHMS.

 

Holdings

 

i.

Sole power to vote or direct the vote:

0

 

 

 

ii.

Shared power to vote or direct the vote:

4,831,247

 

 

 

iii.

Sole power to dispose or direct the disposition of:

0

 

 

 

iv.

Shared power to dispose or direct the disposition of:

4,831,247

 

Holdings shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in OGBBA.

 

Abchrys

 

i.

Sole power to vote or direct the vote:

0

 

 

 

ii.

Shared power to vote or direct the vote:

4,831,247

 

 

 

iii.

Sole power to dispose or direct the disposition of:

0

 

 

 

iv.

Shared power to dispose or direct the disposition of:

4,831,247

 

Abchrys shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of its direct equity interest in Holdings.

 

15


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

Mr. van Herk

 

i.

 

Sole power to vote or direct the vote:

 

0

 

 

 

 

 

ii.

 

Shared power to vote or direct the vote:

 

4,831,247

 

 

 

 

 

iii.

 

Sole power to dispose or direct the disposition of:

 

0

 

 

 

 

 

iv.

 

Shared power to dispose or direct the disposition of:

 

4,831,247

 

Mr. van Herk shares the power to vote or direct the vote of, and to dispose or direct the disposition of, the Common Stock beneficially owned by VHI by virtue of his holding of all of the depositary receipts issued by Penulata and Abchrys, his being the sole board member of Penulata and Abchrys, and his being the sole managing director of VHMS, OGBBA and Holdings.

 

(c)                                  The following transactions with respect to Ordinary Shares were effected by VHI between November 19, 2017 and the date hereof, all on the Euronext Brussels stock exchange:

 

Date

 

Buy/Sell

 

Number of
Shares

 

Price per
Share

 

11/22/2017

 

Buy

 

96,527

 

19.91

 

11/29/2017

 

Buy

 

1,000

 

18.69

 

11/29/2017

 

Buy

 

900

 

18.67

 

12/5/2017

 

Buy

 

600

 

19.33

 

12/5/2017

 

Buy

 

5,000

 

19.13

 

1/8/2018

 

Buy

 

615,427

 

30.69

 

1/10/2018

 

Buy

 

50,000

 

34.67

 

1/10/2018

 

Buy

 

1,500

 

35.64

 

1/10/2018

 

Buy

 

1,600

 

35.66

 

1/10/2018

 

Buy

 

4,000

 

35.70

 

1/10/2018

 

Buy

 

5,000

 

35.70

 

1/10/2018

 

Buy

 

5,000

 

35.66

 

1/10/2018

 

Buy

 

5,000

 

35.64

 

1/10/2018

 

Buy

 

5,000

 

35.74

 

1/10/2018

 

Buy

 

5,000

 

35.72

 

1/10/2018

 

Sell

 

1,200

 

35.84

 

1/10/2018

 

Buy

 

1,400

 

35.88

 

1/10/2018

 

Buy

 

5,000

 

35.68

 

1/10/2018

 

Buy

 

5,000

 

35.62

 

1/10/2018

 

Buy

 

5,000

 

35.60

 

1/10/2018

 

Buy

 

5,000

 

35.58

 

1/10/2018

 

Buy

 

5,000

 

35.54

 

1/10/2018

 

Buy

 

5,000

 

35.54

 

1/10/2018

 

Buy

 

5,000

 

34.52

 

1/10/2018

 

Buy

 

5,000

 

34.54

 

1/10/2018

 

Buy

 

5,000

 

34.74

 

1/10/2018

 

Buy

 

5,000

 

34.70

 

 

16


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

Date

 

Buy/Sell

 

Number of
Shares

 

Price per
Share

 

1/10/2018

 

Buy

 

5,000

 

34.66

 

1/10/2018

 

Buy

 

1,538

 

34.62

 

1/10/2018

 

Buy

 

3,028

 

34.59

 

1/11/2018

 

Buy

 

244,419

 

35.16

 

1/11/2018

 

Buy

 

202,760

 

35.44

 

1/12/2018

 

Buy

 

162,386

 

36.53

 

1/12/2018

 

Buy

 

180,000

 

36.54

 

1/12/2018

 

Buy

 

2,000

 

36.76

 

1/12/2018

 

Buy

 

3,000

 

36.68

 

1/12/2018

 

Buy

 

3,676

 

36.67

 

1/12/2018

 

Buy

 

500

 

36.64

 

1/12/2018

 

Buy

 

4,000

 

36.60

 

1/12/2018

 

Buy

 

3,000

 

36.50

 

1/12/2018

 

Buy

 

4,000

 

36.45

 

1/12/2018

 

Buy

 

4,000

 

36.44

 

1/12/2018

 

Buy

 

4,000

 

36.42

 

1/12/2018

 

Buy

 

4,000

 

36.34

 

1/12/2018

 

Buy

 

6,000

 

36.40

 

1/12/2018

 

Buy

 

4,000

 

36.36

 

1/12/2018

 

Buy

 

6,000

 

36.38

 

1/12/2018

 

Buy

 

6,000

 

36.34

 

1/12/2018

 

Buy

 

8,000

 

36.40

 

1/12/2018

 

Buy

 

8,000

 

36.55

 

1/12/2018

 

Buy

 

180

 

36.66

 

1/12/2018

 

Buy

 

8,000

 

36.56

 

1/12/2018

 

Buy

 

8,000

 

36.54

 

1/12/2018

 

Buy

 

8,000

 

36.48

 

1/12/2018

 

Buy

 

2,500

 

36.54

 

1/12/2018

 

Buy

 

270

 

36.28

 

2/6/2018

 

Sell

 

25,000

 

43.80

 

2/6/2018

 

Sell

 

3,000

 

43.82

 

2/6/2018

 

Sell

 

1,413

 

43.84

 

2/6/2018

 

Sell

 

10,012

 

43.80

 

2/7/2018

 

Sell

 

8,731

 

43.76

 

2/12/2018

 

Sell

 

12,000

 

43.60

 

2/12/2018

 

Sell

 

15,000

 

43.70

 

2/12/2018

 

Sell

 

15,000

 

43.70

 

2/12/2018

 

Sell

 

15,000

 

43.76

 

2/12/2018

 

Sell

 

4,000

 

43.78

 

2/12/2018

 

Sell

 

5,000

 

43.76

 

2/12/2018

 

Sell

 

6,000

 

43.74

 

2/12/2018

 

Sell

 

6,000

 

43.78

 

2/12/2018

 

Sell

 

40,000

 

43.80

 

2/12/2018

 

Sell

 

6,000

 

43.84

 

2/12/2018

 

Sell

 

5,000

 

43.84

 

2/12/2018

 

Sell

 

1,915

 

43.88

 

2/13/2018

 

Sell

 

3,000

 

43.74

 

2/13/2018

 

Sell

 

8,000

 

43.74

 

2/13/2018

 

Sell

 

51

 

43.80

 

2/13/2018

 

Sell

 

1,341

 

43.84

 

2/14/2018

 

Sell

 

8,000

 

43.70

 

2/14/2018

 

Sell

 

3,000

 

43.72

 

2/14/2018

 

Sell

 

2,000

 

43.72

 

2/14/2018

 

Sell

 

3,000

 

43.70

 

2/14/2018

 

Sell

 

7,000

 

43.68

 

2/14/2018

 

Sell

 

3,000

 

43.70

 

2/14/2018

 

Sell

 

5,000

 

43.68

 

2/14/2018

 

Sell

 

6,000

 

43.68

 

2/14/2018

 

Sell

 

3,000

 

43.70

 

2/14/2018

 

Sell

 

5,000

 

43.70

 

2/14/2018

 

Sell

 

5,000

 

43.70

 

2/14/2018

 

Sell

 

7,000

 

43.72

 

2/14/2018

 

Sell

 

4,000

 

43.72

 

2/14/2018

 

Sell

 

4,000

 

43.72

 

2/14/2018

 

Sell

 

5,000

 

43.72

 

2/14/2018

 

Sell

 

3,000

 

43.74

 

2/14/2018

 

Sell

 

3,000

 

43.74

 

2/14/2018

 

Sell

 

5,000

 

43.76

 

2/14/2018

 

Sell

 

3,000

 

43.74

 

2/14/2018

 

Sell

 

7,000

 

43.74

 

2/14/2018

 

Sell

 

8,000

 

43.76

 

2/14/2018

 

Sell

 

10,000

 

43.74

 

2/14/2018

 

Sell

 

6,000

 

43.74

 

2/14/2018

 

Sell

 

7,000

 

43.74

 

2/14/2018

 

Sell

 

7,000

 

43.76

 

2/14/2018

 

Sell

 

8,000

 

43.76

 

2/14/2018

 

Sell

 

8,000

 

43.74

 

2/14/2018

 

Sell

 

659

 

43.78

 

2/14/2018

 

Sell

 

10,995

 

43.76

 

2/15/2018

 

Sell

 

20,000

 

43.74

 

2/15/2018

 

Sell

 

12,000

 

43.76

 

2/15/2018

 

Sell

 

20,000

 

43.76

 

2/15/2018

 

Sell

 

10,883

 

43.78

 

2/16/2018

 

Sell

 

29,117

 

43.78

 

2/16/2018

 

Sell

 

15,000

 

43.78

 

2/16/2018

 

Sell

 

12,000

 

43.80

 

2/16/2018

 

Sell

 

25,000

 

43.82

 

2/19/2018

 

Sell

 

50,000

 

43.86

 

2/19/2018

 

Sell

 

15,000

 

43.86

 

2/19/2018

 

Sell

 

10,127

 

43.86

 

2/20/2018

 

Sell

 

14,873

 

43.86

 

2/20/2018

 

Sell

 

40,000

 

43.88

 

2/20/2018

 

Sell

 

12,000

 

43.96

 

2/21/2018

 

Sell

 

5,500

 

43.96

 

2/21/2018

 

Sell

 

15,000

 

43.96

 

2/21/2018

 

Sell

 

15,000

 

43.94

 

2/21/2018

 

Sell

 

8,000

 

43.94

 

2/21/2018

 

Sell

 

30,000

 

43.96

 

2/21/2018

 

Sell

 

7,000

 

43.96

 

2/21/2018

 

Sell

 

12,000

 

43.96

 

2/21/2018

 

Sell

 

5,000

 

43.96

 

2/21/2018

 

Sell

 

4,255

 

43.96

 

2/22/2018

 

Sell

 

5,000

 

43.94

 

2/22/2018

 

Sell

 

7,192

 

43.94

 

2/23/2018

 

Sell

 

10,000

 

43.94

 

2/23/2018

 

Sell

 

12,000

 

43.94

 

2/23/2018

 

Sell

 

10,000

 

43.94

 

2/23/2018

 

Sell

 

15,000

 

43.94

 

2/23/2018

 

Sell

 

40,000

 

43.92

 

2/23/2018

 

Sell

 

10,000

 

43.94

 

2/23/2018

 

Sell

 

4,953

 

43.96

 

2/23/2018

 

Sell

 

11,668

 

43.94

 

2/23/2018

 

Sell

 

129,205

 

43.93

 

2/26/2018

 

Sell

 

6,000

 

43.94

 

2/26/2018

 

Sell

 

15,000

 

43.94

 

2/26/2018

 

Sell

 

3,000

 

43.92

 

2/26/2018

 

Sell

 

169,586

 

43.93

 

2/28/2018

 

Sell

 

8,000

 

43.82

 

2/28/2018

 

Sell

 

12,000

 

43.82

 

2/28/2018

 

Sell

 

2,000

 

43.78

 

2/28/2018

 

Sell

 

3,000

 

43.78

 

2/28/2018

 

Sell

 

6,000

 

43.78

 

2/28/2018

 

Sell

 

12,000

 

43.78

 

2/28/2018

 

Sell

 

24,165

 

43.78

 

2/28/2018

 

Sell

 

18,360

 

43.78

 

2/28/2018

 

Sell

 

2,488

 

43.82

 

3/1/2018

 

Sell

 

10,000

 

44.00

 

3/1/2018

 

Sell

 

8,000

 

43.98

 

3/1/2018

 

Sell

 

10,000

 

44.00

 

3/1/2018

 

Sell

 

10,000

 

44.00

 

3/1/2018

 

Sell

 

8,000

 

44.00

 

3/1/2018

 

Sell

 

12,000

 

44.00

 

3/1/2018

 

Sell

 

12,000

 

44.02

 

3/1/2018

 

Sell

 

15,000

 

44.00

 

3/1/2018

 

Sell

 

12,000

 

44.00

 

3/1/2018

 

Sell

 

3,903

 

44.02

 

3/1/2018

 

Sell

 

8,000

 

44.02

 

3/1/2018

 

Sell

 

10,000

 

44.04

 

3/1/2018

 

Sell

 

3,082

 

44.06

 

3/1/2018

 

Sell

 

12,866

 

44.04

 

3/1/2018

 

Sell

 

261,893

 

44.00

 

3/2/2018

 

Sell

 

10,000

 

43.91

 

3/2/2018

 

Sell

 

20,000

 

44.00

 

3/2/2018

 

Sell

 

15,000

 

44.00

 

3/2/2018

 

Sell

 

4,000

 

43.95

 

3/6/2018

 

Sell

 

6,004

 

44.00

 

3/7/2018

 

Sell

 

76,193

 

44.00

 

3/8/2018

 

Sell

 

36,575

 

44.01

 

3/8/2018

 

Sell

 

15,000

 

44.04

 

3/9/2018

 

Sell

 

946,077

 

44.00

 

 

The following transactions with respect to Ordinary Shares were effected by Mr. van Herk for the benefit of VHI pursuant to the Account Agreement between November 19, 2017 and the date hereof, all on the Euronext Brussels stock exchange:

Date

 

Buy/Sell

 

Number of
Shares

 

Price per Share

 

11/22/2017

 

Buy

 

500

 

19.94

 

11/22/2017

 

Buy

 

1,000

 

19.95

 

11/22/2017

 

Buy

 

1,200

 

19.94

 

11/22/2017

 

Buy

 

2,000

 

19.95

 

11/22/2017

 

Buy

 

3,000

 

19.96

 

11/29/2017

 

Buy

 

700

 

18.67

 

1/2/2018

 

Buy

 

2,000

 

20.36

 

1/8/2018

 

Buy

 

2,000

 

30.56

 

1/8/2018

 

Buy

 

1,000

 

30.58

 

1/8/2018

 

Buy

 

1,500

 

30.62

 

 

17


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

Date

 

Buy/Sell

 

Number of
Shares

 

Price per Share

 

1/8/2018

 

Buy

 

2,339

 

30.68

 

1/8/2018

 

Buy

 

3,305

 

30.68

 

1/10/2018

 

Buy

 

200

 

34.36

 

1/10/2018

 

Buy

 

300

 

34.38

 

1/10/2018

 

Buy

 

1,000

 

34.32

 

1/10/2018

 

Buy

 

195

 

34.28

 

1/10/2018

 

Buy

 

450

 

35.68

 

1/10/2018

 

Buy

 

378

 

35.66

 

1/10/2018

 

Buy

 

1,200

 

35.70

 

1/10/2018

 

Buy

 

800

 

35.70

 

1/10/2018

 

Buy

 

2,000

 

35.70

 

1/10/2018

 

Buy

 

3,000

 

35.70

 

1/10/2018

 

Buy

 

400

 

35.56

 

1/10/2018

 

Buy

 

800

 

35.52

 

1/10/2018

 

Buy

 

5,000

 

35.44

 

1/10/2018

 

Buy

 

5,000

 

35.42

 

1/10/2018

 

Buy

 

5,000

 

34.36

 

1/10/2018

 

Buy

 

5,000

 

34.44

 

1/10/2018

 

Buy

 

5,000

 

34.48

 

1/11/2018

 

Buy

 

3,000

 

35.00

 

1/11/2018

 

Buy

 

3,000

 

34.94

 

1/11/2018

 

Buy

 

1,215

 

35.48

 

1/11/2018

 

Buy

 

1,000

 

35.46

 

1/11/2018

 

Buy

 

3,000

 

35.40

 

1/11/2018

 

Buy

 

700

 

35.26

 

1/12/2018

 

Buy

 

4,000

 

36.76

 

2/8/2018

 

Buy

 

1,000

 

43.54

 

2/13/2018

 

Sell

 

1,000

 

43.80

 

 

The following transactions with respect to ADSs were effected by Mr. van Herk for the benefit of VHI pursuant to the Account Agreement between November 19, 2017 and the date hereof, all on NASDAQ:

 

Date

 

Buy/Sell

 

Number of
ADSs

 

Price per
ADS

 

11/22/2017

 

Buy

 

1,300

 

$23.48

 

11/22/2017

 

Buy

 

2,000

 

$23.52

 

11/22/2017

 

Buy

 

200

 

$23.51

 

12/8/2017

 

Sell

 

2,000

 

$23.99

 

12/8/2017

 

Sell

 

2,200

 

$23.70

 

12/12/2017

 

Sell

 

250

 

$23.95

 

12/27/2017

 

Sell

 

749

 

$24.20

 

12/28/2017

 

Buy

 

100

 

$24.38

 

12/28/2017

 

Buy

 

748

 

$24.33

 

1/5/2018

 

Buy

 

2,000

 

$25.59

 

1/8/2018

 

Buy

 

1,000

 

$38.63

 

1/8/2018

 

Buy

 

400

 

$39.05

 

 

18


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

Date

 

Buy/Sell

 

Number of
ADSs

 

Price per
ADS

 

1/8/2018

 

Buy

 

500

 

$39.10

 

1/11/2018

 

Buy

 

500

 

$43.22

 

1/11/2018

 

Buy

 

5,000

 

$43.30

 

1/11/2018

 

Buy

 

50

 

$43.20

 

1/12/2018

 

Buy

 

2,000

 

$42.08

 

1/12/2018

 

Buy

 

2,000

 

$42.10

 

1/12/2018

 

Buy

 

100

 

$42.20

 

1/12/2018

 

Buy

 

1,600

 

$42.16

 

1/12/2018

 

Buy

 

300

 

$42.16

 

1/12/2018

 

Buy

 

600

 

$42.36

 

1/12/2018

 

Buy

 

100

 

$42.31

 

1/12/2018

 

Buy

 

300

 

$42.20

 

1/12/2018

 

Buy

 

4,000

 

$42.95

 

1/12/2018

 

Buy

 

200

 

$42.93

 

1/12/2018

 

Buy

 

2,000

 

$42.98

 

1/12/2018

 

Buy

 

3,000

 

$42.95

 

1/12/2018

 

Buy

 

2,000

 

$42.90

 

1/12/2018

 

Buy

 

48

 

$42.84

 

1/12/2018

 

Buy

 

150

 

$42.90

 

1/12/2018

 

Buy

 

60

 

$42.89

 

1/12/2018

 

Buy

 

700

 

$42.99

 

1/12/2018

 

Buy

 

500

 

$42.77

 

1/12/2018

 

Buy

 

1,200

 

$42.60

 

1/12/2018

 

Buy

 

4,000

 

$42.55

 

2/21/2018

 

Buy

 

100

 

$53.88

 

 

(d)                                 Each of the Reporting Persons affirms that no person other than the Reporting Persons has the rights to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock owned by such Reporting Person.

 

(e)                                  Not applicable.

 

Item 6.                                                         Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

There are no contracts, arrangements, understandings or relationships (legal or otherwise) among the persons named in Item 2 and between such persons and any person with respect to the Common Stock, including but not limited to transfer or voting of the Common Stock, finders fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies as of the date hereof.

 

The Reporting Persons reserve the right to write or purchase options on the Common Stock from time to time without notice.

 

Item 7.                                                         Material to be Filed as Exhibits

 

Exhibit 1                                               Press Release, dated January 18, 2018, issued by VHI.

 

19


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

Exhibit 2                                               Schedule 13D Joint Filing Agreement, dated as of March 13, 2018, by and among the Reporting Persons.

 

Exhibit 3                                               Power of Attorney, dated as of February 27, 2018, by and among the Reporting Persons.

 

20


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

SIGNATURES

 

After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

 

Dated:  March 13, 2018

 

 

 

 

VAN HERK INVESTMENTS B.V.

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

 

 

 

VAN HERK PRIVATE EQUITY INVESTMENTS B.V.

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

 

 

 

STICHTING ADMINISTRATIEKANTOOR PENULATA

 

 

 

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

 

 

 

VAN HERK MANAGEMENT SERVICES B.V.

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

 

 

 

ONROEREND GOED BEHEER- EN BELEGGINGSMAATSCHAPPIJ A. VAN HERK B.V.

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

 

 

 

A. VAN HERK HOLDING B.V.

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

21


 

SCHEDULE 13D/A

 

CUSIP No. BE0003877942

 

 

 

 

STICHTING ADMINISTRATIEKANTOOR ABCHRYS

 

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

 

 

 

 

 

 

ADRIANUS VAN HERK

 

 

 

By:

/s/Erik G.A. Esveld

 

Name: Erik G.A. Esveld

 

Title: Attorney-In-Fact

 

22